

DAFTAR PUSTAKA

- Abbas, A. K., Lichtman, A. H., Pillai, S. 2015. The Inflammatory Response. In 8th eds. *Cellular and Molecular Immunology*. Elsevier, pp: 72-80
- Abella, V., Scotece, M., Conde, J., Pino, J., Gonzalez-Gay, M.A., *et al.* 2017. Leptin in the interplay of inflammation, metabolism and immune system disorders. *Nat. Rev. Rheumatol*, 13:100–109.
- Adamson, J. W. 2008. The anemia of inflammation/malignancy: mechanisms and management. *Hematol. Am. Soc. Hematol. Educ. Program*, 159–65.
- Alli, N., Bch, M.B., Sa, F., Vaughan, J., Bch, M.B., Sa, F., Haem, M., Patel, M., Chb, M.B., Sa, F.C.P. & Lond, F. 2017. Anaemia : Approach to diagnosis. *S Afr Med J*, 107(1): 23–27.
- Alvarez, P., Carrasco, R., Dapuetto, C. R., & Castillo, R. L. 2015. Transfusion-Related Acute Lung Injured (TRALI): Current Concepts. *Open Respir Med J*, 9 (Suppl 2: M3):92-96
- Antonio, M. , Clelia, M., Daniela, M., Maria, C. M. 2005. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. *Blood*, 106:362-67.
- Ardestani, S. 2013. New Insights Into Tumor Necrosis Factor-Alpha In Cancer: Distinct Isoforms Exert Opposing Effects On Tumor Associated Myeloid Cells And Tumorigenesis. Dissertation, pp:7-14.
- Anon. 2018. Hasil utama riset kesehatan dasar. hal:1–88.
- Anon. 2011. Purecell ® RC High Efficiency leucocyte removal filter for blood transfusion of 1 unit (EU). <http://pall.com/main/Medical/Product.page?id=48145>.
- Anon. 2016. Quantitative determination of Tumor Necrosis Factor-Alpha. <http://www.biovendor.com>.
- Baumgartner, J. M., Nydam, T. L., Clarke, J. H., Banerjee, A., Silliman, C. C., & McCarter, M. D. 2009. Red Blood Cell Supernatant Potentiates LPS-Induced Proinflammatory Cytokine Response From Peripheral Blood Mononuclear Cells. *J Interferon Cytokine Res*, 29:333-38.
- Barrett-Lee, P. J., Bailey, N. P., O'Brien, M. E. R., Wager, E. 2000. Large-scale UK audit of blood transfusion requirements and anemia in patients receiving cytotoxic chemotherapy. *Br J Cancer*, 82: 93-97.
- Blajchman, M.A. 1997. Allogeneic blood transfusions, immunomodulation and postoperative bacterial infection: do we have the answers yet? *Transfusion*, 37: 121-5.
- Bridges, K. R., Pearson, H. A. 2008. Cancer and Anemia. In *Anemias and Other Blood Disorders*. McGraw-Hill, pp:58-80
- Castro, J. A., Aspiros, A. Z., Cuellar, E. N. A., Perez, B. M., *et al.* 2019. Transfusion related acute lung injury-TRALI: a review. *Int J Res Med Sci*, 7(5):1985-91

- Cetin, A., Sen, A., Cetin, I., Cimen, B., Cimen, L., Savas, G., & Koker, M. Y. 2018. Comparison of ELISA and flowcytometry for measurement of IL-1 β , IL-6 and tumor necrosis factor- α . *Turk J Biochem.* 0 (0).
- Chen, D., Serrano, K. & Devine, D. V. 2016. Introducing the red cell storage lesion. *ISBT Sci Ser*, 11: 26–33.
- Cella, D. 2008. Factors Influencing Quality of Life in Cancer Patients: Anemia and Fatigue. *Semin Oncol*, 25:43-46.
- Curt, G. A. 2000. Impact of Fatigue on Quality of Life in Oncology Patients. *Semin Hematol*, 37:14-17.
- Dahlan, S. 2011. Statistika Untuk Kedokteran dan Kesehatan. In *Salemba Medika*. Jakarta: 167–74.
- Delaney, M., Wendel, S., Bercovitz, R. S., et al. 2016. Transfusion reactions: prevention, diagnosis, and treatment. *The Lancet*, 388(10061).
- Dicato, M., Plawny, L. & Diederich, M. 2010. Anemia in cancer. *Ann Oncol*, 21(7): 167–72.
- Dunning, C. & Lame, M., E. 2018. Development of a Hybrid Immunoaffinity-LCMS/MS Method for the Quantification of Active Biotherapeutics Targeting TNF- α in Serum. *Waters*. 0 0)
- El Amrani, M, van den Broek, MP, Gobel, C, van Maarseveen, EM. 2016. Quantification of Active Infliximab in Human Serum with Liquid Chromatography-Tandem Mass Spectrometry Using a Tumor Necrosis Factor Alpha-based Pre-analytical Sample Purification and a Stable Isotopic Labeled Infliximab Bio-similar as Internal Standard: A Target-based, Sensitive and Cost-effective Method. *J. Chromatogr. A*, 1454:42–48.
- Elzik ME, Dirschl RD, Dahners LE. 2006. Correlation of Transfusion Volume to Change in Hematocrit. *Am J Hematol Oncol*, 81(2):145-146.
- Galel, S.A., Fontaine, M.J., Viele, M.K., Gonzalez, C.L. & Goodnough, L.T. 2013. Transfusion Medicine. In *Wintrobe Clinical Hematology*. pp. 547–86.
- Ganz, T. & Nemeth, E. 2011. Heparin and disorders of iron metabolism. *Annu. Rev. Med*, 62: 347–60.
- Gaspar, B.L., Sharma, P., Das, R. 2015. Anemia in malignancies: pathogenetic and diagnostic considerations. *Hematology*, 20:18–25.
- Gibis, B., and Baladi, J., F. 1998. Leucoreduction: The Techniques used, their effectiveness, and costs. The Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
- Gillespie, T.W. 2003. Anemia in Cancer: Therapeutic Implication and Interventions. *Cancer Nurs*, 26(2):119-28.
- Gordon, M. S. 2002. Managing anemia in the cancer patient: old problems, future solutions. *Oncologist*, 7:331-41
- Graziadei, I., Gaggl, S., Kaserbacher, R., Braunsteiner, H., Vogel, W. 1994. The Acute-phase Protein A1-antitrypsin Inhibits Growth and proliferation of Human Early Erythroid Progenitor Cells (K562) In vitro By Interfering With Transferrin Iron Uptake. *Blood*, 83(1):260-68.
- Grotto, H. Z. 2007. Anaemia of cancer: An overview of mechanisms involved in its pathogenesis. *Med. Oncol*, 25:12–21.

- Harrison, L. B., Shasha, D., White, C., Ramdeen, B. 2000. Radiotherapy-associated anemia: The scope of the problem. *Oncologist*, 5 (Suppl2): 1-7
- Heddle, N.M., Klama, L.N., Griffith, L., et al., 1993. A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions. *Transfusion*, 33 : 794.
- Herault, O., Binet, C., Rico, A., Degenne, M., Bernard, M., Chassaigne, M. & Sensebe, L. 2001. Evaluation of Performance of White Blood Cell Reduction Filters : An Original Flow Cytometric Method for Detection and Quantification of Cell-Derived Membrane Fragments. *Cytometry*, 45: 277–284.
- Honda, K., Ishiko, O., Tatsuta, I., Deguchi, M., Hirai, K., Nakata, S. 1995. Anemia-inducing Substance from Plasma of Patients with Advanced Malignant Neoplasms. *Cancer Res*, 55:3623-28.
- Hoffbrand, A.V., Moss, P. A. 2016. Erythropoiesis and general aspects of anaemia. In 7th eds. *Essential Haematology*. Wiley-Blackwell., pp. 12-26.
- Hsu, Y.S., Ness, P.M., Cushing, M.M. & Cells, R.B. 2018. Principles of Red Blood Cell Transfusion. In R. Hofmann, E. Benz, L. Silberstein, H. Heslop, J. Weitz, & J. Anastasi, 7th eds. *Hematology*. Elsevier Inc., pp. 1702–14.
- Ishida, A. 2005. Examination and treatment for dilutional thrombocytopenia. *Rinsho Byori Jpn J Clin Pathol*. 53(7) : 654-657
- Jammal, M. P., Da Silva, A. A., Filho, A. M., De Castro Cobo, E., Adad, S. J., Murta, E. F. C., & Nomelini, R. S. 2014. Immunohistochemical staining of tumor necrosis factor- α and interleukin-10 in benign and malignant ovarian neoplasms. *Oncol Lett*, 9: 979-983
- Jöhner, K., Janke, K., Krugmann, J. et al. 2004. Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)- α via TNF receptor 2 and autocrine upregulation of MCP-1. *Clin Cancer Res*, 10;01-10.
- Jourdan, M., Tarte, K., Legouffe, E. et al. 1999. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. *Eur Cytokine Netw*, 10;65-70.
- Kamilah, D. and Widyaningrum, D. 2019. Hubungan jenis *packed red cell* (PRC) yang ditransfusikan dengan reaksi transfusi *febrile non haemolytic transfusion reaction* (FNHTR). *Intisari Sains Medis*, 10 (1): 227-31
- Keir, A. K., Andrew, J. McPhee, Chad, C., Andersen and Stark, M. J. 2013. Plasma cytokines and markers of endothelial activation increase after packed red blood cell transfusion in the preterm infant. *Pediatric Research*, 73(1):75-79
- Kitagawa, M., Saito, I., Kuwata, T., Yoshida, S., Yamaguchi, S., Takahashi, M., Tanizawa, T., Kamiyama, R., & Hirokawa, K. 1997. Overexpression of tumor necrosis factor (TNF)- α and interferon (IFN)- γ by bone marrow cells from patients with myelodysplastic syndromes. *Leukemia*, 11:2049–2054
- Li, H., Tian, J., Cheng, H., Zhang, H., Zhang, D. 2016. Association of tumor necrosis factor alpha polymorphisms with cervical cancer in a Chinese population. *Int J Clin Exp Pathol*, 9(2):2200-2207
- Lin, J. S., Tzeng, C. H., Hao, T. C., Hu, H. Y., Ho, Y. T., Lyou, J. Y., Liu, J. M., Ho, C. H., & Yung, C. H. 2002. Cytokine release in febrile non-haemolytic red cell transfusion reactions. *Vox Sang*, 82:156–160

- Littlewood, T.J. 2001. Effect of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: result of a randomized, double-blind, placebo controlled trial. *J. Clin. Oncol*, 19 (11):2865-74.
- Ludwig, H., Van Belle, S., Barrett-Lee, P., Birgegård, G., Bokemeyer, C., Gascón, P. 2004. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence & treatment of anaemia in cancer patients. *Eur. J. Cancer*, 40: 2293–2306.
- Macciò, A., Gramignano, G. & Madeddu, C. 2015. A multitargeted treatment approach for anemia and cachexia in metastatic castration-resistant prostate cancer. *J. Pain Symptom Manage*, 50:e1–e4.
- Madeddu, C., Gramignano, G., Astara, G., Demontis, R., Sanna, E., Atzeni, V. & Macciò, A. 2018. Pathogenesis and Treatment Options of Cancer Related Anemia : Perspective for a Targeted Mechanism-Based Approach. *Front. Phys*, 9: 1–20.
- Mantovani, G., Macció, A., Mura, L., Massa, E., Mudu, M.C., Mulas, C., *et al.* 2000. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. *J. Mol. Med.* 78: 554–61.
- Mccarthy, J., Unilever, R. & Colworth, D. 2013. Immunological techniques : ELISA. In *Detecting pathogens in food*. Woodhead Publishing Limited, pp. 241–58.
- Méndez-García, L.A., Nava-Castro, K.E., Ochoa-Mercado, T., Palacios-Arreola, M.I., Ruiz-Manzano, R.A., Segovia-Mendoza, M., Solleiro-Villavicencio, H., *et al.* 2018. Breast Cancer Metastasis: Are Cytokines Important Players During Its Development and Progression? *J. Interferon Cytokine Res*, 39(1): 39-55.
- Menis, M., Forshee, R.A., Anderson, S. A., McKean, S., *et al.* 2015. Febrile non-haemolytic transfusion reaction occurrence and potential risk factors among the U.S elderly transfused in the inpatient setting, as recorded in Medicare databases during 2011–2012. *Vox Sang*, 108(3):251-61.
- Menitove, J.E. 1999. Standards for blood banks and transfusion services. 19th ed. Bethesda MD: *Am Assoc of Blood Banks*.pp. 1- 20.
- Mercogliano, M. F., Bruni, S., Elizalde, P. V., & Schillaci, R. 2020. Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer. *Front. Oncol*, 10:584.
- Miguel, J.F., Garcia, S.R. 1998. Recombinant human erythropoietin in the anaemia of multiple myeloma and nonHodgkin's lymphoma. *Med Oncol*, 15 (suppl 1):29-34.
- Mohandas, K., Aledort, L. 1995. Transfusion requirements, risks, and costs for patients with malignancy. *Transfusion*. 35(5):427-30.
- Müller, M.M., Geisen, C., Zacharowski, K., Tonn, T. & Seifried, E. 2015. Transfusion of Packed Red Cells. *Dtsch Arztebl Int*, 112:507-18.
- Muyllé, L., Joos, M., Wouters, E., *et al.* 1993. Increased Tumor Necrosis Factor α (TNF- α), interleukin 1, and interleukin 6 levels in the plasma of stored platelet concentrates; relationship between pro inflammatory cytokine levels and febrile transfusion reactions. *Transfusion*, 33(3): 195-199.

- Naylor, M. S., Stamp, G. W. H., Foulkes, W. D., Eccles, D., Balkwill, F. R. 1993. Tumor necrosis factor and its receptors in human ovarian cancer: potential role in disease progression. *J Clin Invest*, 91:2194–2206.
- National Cancer Institute. 2009. Common terminology criteria for adverse events (CTAE). <https://evs.nci.nih.gov> > CTAE > Archive. (5 Desember 2018).
- Nikiteas, N. I., Tzanakis, N., Gazouli, M., Rallis, G., Danilidis, K., Theodoropoulos, G., Kostakis, A. & Peros, G. 2005. Serum IL-6, TNF- α , and CRP levels in Greek Colorectal Cancer Patients: Prognostic implications. *World J Gastroenterol*, 11(11):1639-1643
- Nowrousian, M. R. (ed). 2002. *Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology*. © Springer-Verlag/Wien 2002
- Oliver, J. C., Bland, L. A., Oettinger, C. W., Arduino, M.J., McAllister, S. K., Agüero, S. M., & Favero. 1993. Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge. *Lymphokine Cytokine Res*, 12(2):115-20.
- Page, M. J., Bester, J., Pretorius, E. 2018. The inflammatory effects of TNF- α and complement component 3 on coagulation. *Scientific Reports*, 8:1812
- Panch, S. R., Garcia, C. M., & Klein, H. G. 2019. Hemolytic Transfusion Reactions. *N Engl J Med*, 381:150-62.
- Parnes, A., Nikiforow, S., Berliner, N. *et al.* 2010. Single nucleotide polymorphisms in the human TNF gene are associated with anaemia and neutropenia in a cohort of patients with de novo myelodysplastic syndrome. *Br J Haematol*, 150:700-1
- Pasricha, S. R., Colman, K., Tablante, E. C., Casal, M. N. G. & Rosas, J. P. P. R. 2018. Revisiting WHO haemoglobin thresholds to define anaemia in clinical medicine and public health. *Lancet haematology*, 5(1):e60-e62
- Playfair, J.H.L. & Chain, B.M. 2009. Investigating immunity. In *Immunology at a Glance*. Wiley-Blackwell, pp. 96–99.
- Purcell, S.L., Melissa, C., Hosgood, G. & Smart, L. 2015. Effect of leukoreduction on concentrations of interleukin-8, interleukin-1 β , and tumor necrosis factor- α in canine packed red blood cells during storage. *Am J Vet Res*, 76(11): 969–974.
- Qu, X., Tang, Y., & Hua, S. 2018. Immunological Approaches Towards Cancer and Inflammation: A cross Talk. *Front. Immunol.* 9:563.
- Rajesh, K., Harsh, S., Amarjit, K. 2015. Effects of Prestorage Leukoreduction on the Rate of Febrile Nonhemolytic Transfusion Reactions to Red Blood Cells In A Tertiary Care Hospital. *Ann Med Health Sci Res*, 5(3):185-8
- Remy, K. E., Hall, M. w., Cholette, J., et al. 2018. Mechanisms of red blood cell transfusion-related immunomodulation. *Transfusion*, 58:804–815
- Rodgers, G. M., Gilreath, J. A., Achebe, M. M., Alwan, L., Arcasoy, M., Ali Beth, S. 2017. *NCCN. Cancer- and Chemotherapy-Induced Anemia, Version 2.2017*. http://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf (27 Desember 2018).
- Ruggiero, A., Riccardi, R. 2002. Interventions for anemia in pediatric cancer patients. *Med Pediatr Oncol*, 39: 451–54.

- Rutten, S., Schusser, G. F., Abraham, G., & Schrod, W. 2016. Release kinetics of tumor necrosis factor- α and interleukin-1 receptor antagonist in the equine whole blood. *BMC Veterinary Research*, 12:117
- Saba, H. I. 1998. Anemia in Cancer Patients : Introduction and Overview. *Cancer Control*, 5(2):1-7.
- Sabbatini P. 2000. Treating Cancer Symptoms Improves Quality of Life:Part 1. Treatment of Anemia and Fatigue. *Int J Pharmacol*, 14:88-91.
- Sastroasmoro & Ismael, S. 2014. Dasar-dasar Metodologi Penelitian Klinis.pp:13–29.
- Schneider, S. O., Rensing, H., Gräber, S., *et al.* 2000. Impact of platelets and fresh frozen plasma in contrast to red cell concentrate on unstimulated and stimulated cytokine release in an *in vitro* model of transfusion. *Scand J Immunol*,70:101–5.
- Schmidt, P.J. 2015. Regulation of iron metabolism by hepcidin during conditions of inflammation. *J. Biol. Chem*, 290: 18975–83.
- Schrijvers, D. 2011. Oncologist Management of Anemia in Cancer Patients : Transfusions. *The Oncologist*, 16(suppl 3): 12–18.
- Setrerrahmane, S., Xu, H. 2017. Tumor-related interleukins: old validated targets for new anti-cancer drug development. *Mol Cancer*, 16:153.
- Shabir, G. 2004. A practical approach to validation of HPLC methods under current good manufacturing practices. *J. Val. Tech*, 29–37.
- Shanwell, A. 1997.Generation of cytokines in red cell concentrates during storage is prevented by prestorage white cell reduction. *Transfusion*, 37:678-84.
- Shih, A. W., Bhagirath, V. C., Heddle, N. M., Acker, J. P., Liu, Y., Eikelboom, J. W., Liaw, P. C. 2016. Quantification of Cell-Free DNA in Red Blood Cell Units in Different Whole Blood Processing Methods. *J Blood Transfus*, 2016:9316385
- Shukla, R., Patel, T. & Gupte, S. 2015. Release of cytokines in stored whole blood and red cell concentrate: Effect of leukoreduction. *Asian J Transfus*, 9:145-9
- Silva, L. B., dos Santos Neto, A. P., Maia, S. M. A. S., *et al.* 2019. The Role of TNF- α as a Proinflammatory Cytokine in Pathological Processes. *Open Dent. J*, 13:333-38
- Simancas, R., Osorio, D. & Arturo J, M. 2015. Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion (Review). *Cochrane Database of Systematic Reviews 2015*, (12): 1–74.
- Smith, K.J., Sierra, E.R. & Nelson, E.J. 1993, Histamine, IL-I, and IL-8 increase in packed RBCs stored for 42 days but not in RBCs leukodepleted pre-storage. *Transfusion*, 33(Supp1) :53S.
- Sut, C., Tariket, S., Chou, M. L., Garraud, O., Laradi, S., Cognase, H. H., Seghatchian, J., Burnout, T. & Cognase, F. 2017. Duration of red blood cell storage and inflammatory marker generation. *Blood Transfus*,15:145-52.
- Stanilov, N., Miteva, L., Dobрева, Z.& Stanilova, S. 2014. Colorectal cancer severity and survival in correlation with tumour necrosis factor alpha. *Biotechnol Biotechnol Equip*, 3; 28(5): 911–917.

- Straat *et al.* 2016. Extracellular vesicles from red blood cell products induce a strong proinflammatory numbers and storage duration. *Transfus Med Hemother*, 43:302-5.
- Spivak, J. L. 2005. The anaemia of cancer: death by a thousand cuts. *Nat. Rev. Cancer*, 5: 543–55.
- Stack, G., Baril, L., Napychank, P. & Snyder, E.. 1995. Cytokine generation in stored, white cell-reduced, and bacterially contaminated units. *Transfusion*, 35: 199–203.
- Srihartaty, Soedarmono, Y. S. M., Wahidiat, P. A. 2014. Perbedaan penurunan jumlah leukosit dan sitokin pada *Packed Red Cell* dengan metode *buffy-coat depleted* dan modifikasi *bed-side leucocyte filtration*. *J. Indon Med Assoc*, 64:447-50
- Sutandyo, N. 2007. Transfusi pada pasien kanker: manfaat dan resiko. *Indonesian J. Cancer*, 3:115-20.
- Szlosarek, P., Charles, K. A., & Balkwill, F. R. 2006. Tumour necrosis factor- α as a tumour promoter. *Eur J Cancer*, 42:745 – 750
- Tamimi, A. S. & Dheeb, I. A. 2019. Level of pro-inflammatory cytokines in patients with transfusion related acute lung injury-Multiple comparisons between patients, controls, and donor. *Int J. Res. Pharm. Sci*, 10(2):1448-55
- Tian, T., Wang, M., Ma, D. 2014. TNF- α , a good or bad factor in hematological diseases? *Stem Cell Investig*, 1:12
- Turner, M. D., Nedjai, B., Hurst, T., & Pennington, D. J. 2014. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. *Biochim. Biophys. Acta*, 20:1-10
- Vamvakas, E.C., Blajchman, M.A. 2001. Universal WBC reduction : the case for and against. *Transfusion*, 41: 691-712.
- Vucic, M., Stanojkovic, Z., Antic, A., Vucic, J., & Pavlovic, V. 2018. Evaluation of platelet activation in leukocyte-depleted platelet concentrates during storage. *Bosn J Basic Med Sci*. 18(1):29-34.
- Waters, J. P., Poher, J. S., & Bradley, J. R. 2013. Tumor necrosis factor and cancer. *Journal of Pathology*, 230:132-47.
- Weiss, G. & Goodnough, L. T. 2005. Anemia of chronic disease. *N. Engl. J. Med*, 352: 1011–23.
- Wiesen AR, Hospenthal DR, Byrd JC, Glass KL, Howard RS, *et al.* 1994. Equilibration of Hemoglobin Concentration after Transfusion in Medical Inpatients Not Actively Bleeding. *Ann Intern Med*, 121(4): 278-280.
- World Health Organization. 2020. WHO report on cancer: setting priorities, investing wisely and providing care for all. <https://www.who.int/cancer/en/> (4 Agustus 2020).
- Zarbock, A, Ley, K. 2009. Neutrophil adhesion and activation under flow. *Microcirculation*, 16:31–42.
- Zidi, I., Mestiri, S., & Bartegi, A. 2010. TNF- α and its inhibitors in cancer. *Med Oncol*, 27:185–198